A new treatment for malaria could be on the way with the announcement that the Medicines for Malaria Venture (MMV) and Anacor Pharmaceuticals have entered into a development agreement relating to an Anacor compound - AN3661.
MMV is a not-for-profit public-private partnership that aims to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. Anacor is a US biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.
Under the agreement, Anacor and MMV will work together on the development of AN3661 through human proof-of-concept studies. AN3661 was developed as part of a research agreement signed last year; AN3661 is the first candidate arising out of this agreement to move into preclinical development.
Anacor is also active in the search for treatments for other infectious diseases of poverty and has established partnership arrangements with: the Global Alliance for TB Drug Development; with the Drugs for Neglected Diseases initiative (human African trypanosomiasis, visceral leishmaniasis and Chagas disease); the University of California San Francisco and the New York Blood Center (onchocerciasis); and with the Institute for OneWorld Health (diarrhoeal disease.)
More details are available in an Anacor press release.